In This Article:
This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community.
LOS ANGELES - March 11, 2025 (NEWMEDIAWIRE) - Calidi Biotherapeutics (NYSE American: CLDI) announced positive preclinical results for its systemic RTNova platform, demonstrating effective delivery of transient gene therapy payloads to targeted tumors. The tumor-specific virotherapy has shown efficacy across more than 60 tumor cell lines, with a unique vaccinia virus strain enveloped in a human cell membrane providing protection in the bloodstream while targeting distant tumors. In preclinical models, a single dose of the tumor-selective triple knockout ("3KO") RT virus with an undisclosed immunotherapeutic payload significantly altered the tumor microenvironment, leading to complete tumor eradication in some cases. The findings support the platform's potential to revolutionize cancer treatment by enabling both tumor destruction and robust immune activation.
To view the full press release, visit https://ibn.fm/CGZoA
About Calidi Biotherapeutics
Calidi Biotherapeutics specializes in proprietary technology that empowers the immune system to combat cancer. The company's novel stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi's clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi's preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to CLDI are available in the company's newsroom at https://ibn.fm/CLDI
Forward-Looking Statements
Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law.